Nuclear factor-κ B (NFκ B) is a central transcription factor orchestrating innate and adaptive immune responses. In acute inflammation, NFκ B activity is tightly regulated. However, aberrantly activated NFκ B is associated with chronic inflammatory diseases and a variety of human cancers including both solid and hematopoietic malignancies. Cancers such as T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma (CTCL), and its leukemic variant, Sézary Syndrome, revealed constitutive NFκ B activity [1] [2] [3] [4] . The NFκ B family consists of five Rel related proteins: RelA (p65), RelB, cRel, p50 and p52, which can form both homo-and heterodimers. The typical NFκ B complex is a p65/p50 heterodimer critical for NFκ B mediated anti-apoptotic effects 5 . In its inactive form, NFκ B is sequestered in the cytoplasm by Iκ Bα . Phosphorylation and proteasomal degradation of Iκ Bα releases NFκ B. Subsequent nuclear translocation and full activation of NFκ B is redox-dependent and mediated by phosphorylation 6 . The redox regulator Thioredoxin-1 (Trx1) promotes DNA binding activity of NFκ B by reduction of a cysteine residue within its DNA binding domain 7, 8 . During oncogenesis, NFκ B promotes cell survival and proliferation by inducing expression of molecules associated with suppression of programmed cell death (PCD), such as cFLIPs 9 , IAP proteins 6,10 , and members of the Bcl-2 family 11 . PCD is a mechanism of tumor suppression and manifests itself in, e.g. apoptosis and necroptosis. Necroptosis is a form of regulated necrosis, which has been implicated to trigger strong immune responses by release of damage-associated molecular patterns (DAMPs) 12 . Moreover, necroptosis is critical for T-cell homeostasis as backup to eliminate an excess of activated T-cells after clonal expansion preventing autoimmunity 13 . The ripoptosome is a signaling platform triggering cell death in an apoptotic or necroptotic manner [14] [15] [16] . The core components of the ripoptosome include caspase-8, FADD (Fas-associated death domain) and RIPK1 (Receptor-interacting kinase 1). Formation and activation of the ripoptosome are negatively regulated by IAPs (cIAP1, cIAP2 and XIAP) and cFLIPs (cFLIP L and cFLIP S ), respectively. IAPs are regulated by Smac (Second
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Here, we show that DMF (Tecfidera ® ), a FDA-approved drug for treatment of multiple sclerosis, blocks Trx1 activity by modification of a specific thiol group. Reduced Trx1 activity leads to inhibition of NFκ B. Remarkably, DMF-mediated inhibition of the Trx1/NFκ B axis results in ripoptosome formation and subsequent PCD by downregulation of cIAP2 and cFLIPs in vitro and in vivo. Full ripoptosome activation requires mitochondria and release of Smac. Cytosolic Smac promotes degradation of cIAP1 and XIAP, further enhancing ripoptosome formation and activation in an amplification loop. Moreover, DMF treated Sézary patients reveal ripoptosome assembly which coincides with caspase-3 cleavage. DMF administration induced cell death more efficiently in malignant CD4
+ T-cells isolated from Sézary patients compared to resting T-cells. Other than apoptosis which is induced in T-cells from Sézary patients and healthy donors, necroptosis predominantly occurs in malignant T-cells.
Hence, targeting the Trx1/NFκ B signal transduction by DMF may represent a promising treatment for lymphoproliferative diseases. Our data further provide a rationale for the development of novel compounds treating NFκ B dependent tumors.
Results

DMF suppresses activity of Trx1 by monomethyl succinylation. DMF is a potent inhibitor of
NFκ B 21 , though the molecular mechanism by which DMF suppresses transcriptional activity of NFκ B is unclear. DMF has been shown to modify reactive thiol groups in e.g. glutathione (Supplementary Data and Supplementary Fig. S1A ) 22 . Together with glutathione, thioredoxin proteins (Trx1 and Trx2) control cellular reactive oxygen species (ROS). In addition, Trx1 controls the redox state of cysteine residues in proteins such as NFκ B 23 . Therefore, we set out to determine whether inhibition of NFκ B is mediated by DMF-dependent suppression of Trx1.
Mass spectrometry (MS) was used to identify chemical modifications of Trx1 in response to DMF. Interestingly, the redox sensitive cysteines (C32 and C35) have not been targeted. However, C73, which possesses a regulatory function controlling general activity of Trx1 [24] [25] [26] [27] , was identified as monomethyl succinylated (Fig. 1A , Supplementary Fig. S1B-D) . Notably, we detected no modification of Trx2. Equal concentrations of MMF (25 μ M), a hydrolization product of DMF, did not result in detectable modifications of Trx1 (data not shown).
To investigate the impact of monomethyl succinylation activity of Trx1 was determined. Modification of Trx1 led to an inhibition of its activity. PMX464, a known Trx inhibitor 28 , was used as positive control (Fig. 1B) . Furthermore, DMF-dependent suppression of Trx1 resulted in elevated levels of ROS. Treatment with trolox, a water-soluble vitamin E derivative and thiol-independent antioxidant, blocked DMF-dependent ROS accumulation (Fig. 1C) . Thus, monomethyl succinylation of C73 by DMF inhibits Trx1 activity.
NFκB inhibition by DMF induces loss of cIAP2 and cFLIP. As a regulator of NFκ B transcriptional activity Trx1 is an attractive target for cancer therapy. Trx1 promotes transcriptional activity of NFκ B by reducing a cysteine in its DNA binding domain 23 . To evaluate the redox state of NFκ B upon DMF treatment, proteins containing free thiols were precipitated. Inhibition of Trx1 in response to DMF led to a time-dependent accumulation of inactive/oxidized NFκ B. Cysteines in NFκ B were oxidized 2 h after DMF treatment ( Fig. 2A) . Similarly, PMX464 suppressed reduction of cysteines in NFκ B (Supplementary Fig. S2A ).
Oxidized cysteines in NFκ B should result in diminished DNA binding. Therefore, we tested DNA binding of NFκ B on target genes such as Birc2, Birc3, Xiap, Cflar, Bcl-2 and Bcl2l1. DNA oligonucleotides with NFκ B binding sites were pulled-down and probed for the presence of NFκ B. DNA binding of NFκ B to oligonucleotides of Birc2, XIAP and Bcl-2 was not regulated in response to DMF. However, DMF treatment suppressed NFκ B binding to Birc3, Cflar and Bcl2l1 ( Fig. 2B; Supplementary Fig. S2B ). Consistently, DMF inhibited mRNA and protein expression of cIAP2 and cFLIPs (Fig. 2C,D) . However, Bcl XL expression was only moderately impaired on mRNA and protein level (Fig. 2C,D) . Bcl-2 was not regulated in response to DMF ( Fig. 2D; Supplementary Fig. S2C ).
Collectively, our data demonstrate that inhibitors of Trx1 such as DMF and PMX464 suppress reduction of cysteines in NFκ B. DMF-dependent oxidation of cysteines in NFκ B results in diminished expression of cIAP2 and cFLIPs ( Supplementary Fig. S2D ).
Inhibition of NFκB activity results in ripoptosome formation. NFκ B inhibition by DMF caused cell death in HH, SeAx and CEM cells in a dose-and time-dependent manner ( Supplementary Fig. S3A ). Since Trx1 inhibition by DMF triggered ROS accumulation, we tested whether ROS is the source for cell death.
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However, cell death mediated by DMF was independent of ROS. Trolox diminished ROS accumulation upon DMF treatment (Fig. 1C) , but failed to rescue DMF-induced cell death ( Supplementary Fig. S3B ). Thus, ROS and Iron-dependent cell death can be excluded 29 . Instead, cell death mediated by DMF was facilitated by caspase-8 and -3 activation ( Fig. 3A; Supplementary Figure S3C) . Importantly, activation of caspase-8 and -3 was independent of extrinsic death ligands. DMF failed to stimulate mRNA expression of CD95L, TNFα and TRAIL in malignant T-cells ( Supplementary Fig. S4A ). In addition, treatment with inhibitors for CD95L (APG101), TNFα (Enbrel) and TRAIL (TRAIL-Fc), either alone or in combination, had no effect on cell death induced by DMF ( Supplementary Fig. S4B,C) .
Since no extrinsic ligands were involved in caspase activation upon NFκ B inhibition, we set out to determine whether an intrinsic cell death platform called the ripoptosome facilitates PCD. Ripoptosome formation is blocked by IAPs. Downregulation of IAPs upon DMF administration (Fig. 2D ) coincided with elevated caspase-8 activity (Fig. 3A) . It was reported that RIPK1 is negatively regulated by caspase-8 and FADD once incorporated in the ripoptosome complex. Active caspase-8 cleaves RIPK1 after D324, thus, promoting apoptosis but inhibiting necroptosis 30 . Consistent with DMF-induced kinetics of caspase-8 activation (Fig. 3A ) RIPK1 was cleaved upon DMF administration ( Fig. 3B; Supplementary Fig. S4D ). Abrogation of caspase activity by zVad application rescued RIPK1 cleavage in DMF treated cells suggesting complex formation of caspase-8 with RIPK1. As expected, loss of cIAP2 expression was not influenced upon zVad administration (Fig. 3B) .
Birc3 fold ind. To elucidate ripoptosome assembly in response to DMF, we tested interaction of caspase-8 with RIPK1 and FADD using the proximity ligation assay. Fluorescent signals from interaction of caspase-8 with RIPK1 or FADD were detected in response to DMF (Supplementary Fig. S4E ). Accordingly, DMF treatment triggered co-immunoprecipitation of caspase-8 with FADD and RIPK1 in CEM and SeAx cells (Fig. 3C,  Supplementary Fig. S4F ). Complex formation of caspase-8 and RIPK1 occurred 4-8 h after DMF exposure in SeAx cells and was most robust after 24 h in CEM cells ( Fig. 3D; Supplementary Fig. S4G ). To further establish that loss of NFκ B activity triggered ripoptosome formation additional inhibitors of the NFκ B signaling pathway (PMX464 and NBDII) were tested. Similar to DMF, PMX464 blocks NFκ B activity by suppressing Trx1 (Supplementary Fig. S2A ) 28 . NBDII (NEMO binding domain peptide) antagonizes the interaction of NEMO with the IKK complex and, therefore, suppresses NFκ B activation. Administration of PMX464 and NBDII revealed that inhibition of the NFκ B signaling pathway resulted in ripoptosome formation. Etoposide, which causes depletion of IAPs and subsequent ripoptosome-dependent cell death 14 , was used as positive control (Fig. 3C,  Supplementary Fig. S4F ).
Since DMF-mediated inhibition of NFκ B resulted in decreased cIAP2 expression most efficiently, we tested whether knock-down of Birc3 led to ripoptosome-dependent cell death. siRNA-mediated knock-down of about 60% resulted in moderate ripoptosome assembly and subsequent PCD (Fig. 3E) . Thus, our data indicate that antagonizing NFκ B activity induces ripoptosome formation, which is mediated by cIAP2 downregulation.
Activation of the mitochondrial pathway is required for ripoptosome assembly and ripoptosomedependent cell death. IAPs are negative regulators of ripoptosome formation. cIAP2 was downregulated in response to DMF-dependent NFκ B suppression, which resulted in ripoptosome assembly. To evaluate whether additional IAPs were involved in DMF-mediated assembly of the ripoptosome, we tested the role of cIAP1 and XIAP. cIAP1 and XIAP mRNA expression was not altered upon DMF administration ( Supplementary Fig. S5A ). However, protein expression was impaired in response to DMF after 4-8 h suggesting an additional mechanism that led to decreased protein levels of cIAP1 and XIAP ( Supplementary Fig. S5B ).
Caspase-8 can activate downstream effector caspases such as caspase-3 directly. Simultaneously, caspase-8 can induce Bid cleavage. Bid cleavage was observed 4-8 h after DMF administration ( Supplementary Fig. S5C ). Cleaved Bid results in MOMP and subsequent release of pro-apoptotic molecules such as cytochrome c and Smac 31 . Since Smac has been reported to promote degradation of IAPs, we tested whether Smac was released by mitochondria in response to NFκ B inhibition. Indeed, DMF-mediated Smac release occurred most robustly after 4-8 h, which coincided with a decrease in cIAP1 and XIAP protein levels (Fig. 4A,B and Supplementary Fig. S5B ). Release of Smac was caspase-dependent since inhibition of caspase-8 resulted in decreased Smac translocation from mitochondria (Fig. 4C) . Moreover, inhibition of caspase-8 led to recovery of decreased protein expression levels of cIAP1 and XIAP but not cIAP2 (Fig. 4D) . This is consistent with previous results showing that cIAP2 expression was regulated by NFκ B activity (compare Fig. 2) . Thus, downregulation of cIAP2 in response to DMF results in Smac release from the mitochondria and in degradation of XIAP and cIAP1.
Next, we evaluated whether Smac release and subsequent degradation of IAPs was necessary for ripoptosome-dependent cell death. Therefore, we used Bcl XL overexpressing cells (CEM
BclXL
) and compared them with control CEM cells (CEM Neo ). Bcl XL inhibits MOMP-dependent release of mitochondrial contents such as Smac. In CEM Neo cells DMF diminished mitochondrial membrane potential. In contrast, overexpression of Bcl XL abolished MOMP (Fig. 5A) . Interestingly, Bcl XL overexpression diminished ripoptosome-dependent cell death suggesting that involvement of mitochondria is critical for DMF-mediated PCD (Fig. 5B) . In concert, Bcl XL suppressed cleavage of caspase-9 and caspase-3 in response to DMF. Surprisingly, DMF administration resulted in reduced caspase-8 cleavage in CEM BclXL cells. In addition, caspase-8-dependent RIPK1 cleavage was rescued by Bcl XL suggesting that mitochondria are critical for ripoptosome formation and subsequent cell death (Fig. 5C) . Indeed, Bcl XL diminished complex formation of RIPK1/FADD/caspase-8 in response to DMF indicating an essential mitochondrial amplification loop, which promotes ripoptosome assembly (Fig. 5D) .
To further characterize PCD we compared the effect of DMF with PMX464, etoposide, and LCL161. LCL161 is a Smac mimetic, which induces assembly of the ripoptosome by depleting IAPs 32 . Similar to DMF treatment, induction of MOMP in response to PMX464, etoposide, or LCL161 was diminished by Bcl XL (Fig. 5A) . PCD was rescued by Bcl XL upon PMX464 or etoposide administration. However, LCL161 treated CEM BclXL cells revealed moderate inhibition of PCD (Fig. 5B) . This is in line with caspase cleavage and complex formation. Assembly of the ripoptosome and caspase cleavage upon LCL161 administration was only moderately inhibited suggesting that the Smac mimetic is less dependent on MOMP-mediated Smac release (Fig. 5C,D) . In contrast, Bcl XL diminished complex formation and caspase cleavage in response to etoposide (Fig. 5C,D) indicating that both, DMF and etoposide require mitochondria for ripoptosome-dependent cell death. Thus, overexpression of Bcl XL inhibits mitochondrial Smac release and subsequent degradation of IAPs (e.g. cIAP1 and XIAP) in response to DMF. Collectively, these data suggest that reduction of cIAP2 in response to DMF-induced NFκ B inhibition results in moderate ripoptosome formation. However, to enhance cell death, sufficient assembly and activation of the ripoptosome requires a caspase-8-dependent mitochondrial amplification loop characterized by MOMP and Smac-induced degradation of cIAP1 and XIAP.
Ripoptosome-dependent cell death in human malignant T-cells occurs in an apoptotic and necroptotic manner. CTCL, including its leukemic variant Sézary syndrome, is characterized by a CD4
+ , CD45RO
+ and CD8 − phenotype and an elevated expression of constitutively active NFκ B accompanied by resistance to PCD 2, 20, 33 . DMF is a potent inhibitor of NFκ B activity and was reported to induce apoptosis in stimulated human T-cells 34 .
CD4
+ T-cells were isolated from Sézary patients (Supplementary Table 1) , which revealed elevated levels of phosphorylated NFκ B, cIAP2 and cFLIP compared to healthy controls (Supplementary Fig. S6A ). To evaluate the Scientific RepoRts | 7:43168 | DOI: 10.1038/srep43168 impact of DMF treatment on malignant human T-cells, we first measured specific cell death of DMF-treated primary resting and malignant CD4 + T-cells. NFκ B inhibition by DMF led to increased PCD in T-cells isolated from Sézary patients (Fig. 6A) . To determine the mode of cell death upon NFκ B inhibition, apoptosis was distinguished from necroptosis by Annexin V-FiTC/7AAD uptake (Fig. 6B,C) . Interestingly, zVad protected resting CD4 + cells from PCD but only marginally inhibited DMF-induced cell death in malignant T-cells. Here, zVad administration promoted necroptosis in almost all patient samples since zVad reduced the Annexin V-FiTC positive population, but did not affect the appearance of double-positive cells. Only the combination of zVad with the RIPK1 inhibitor Necrostatin-1 (Nec-1) protected cells from DMF-induced PCD (Fig. 6B,C; Supplementary Fig. S6B ). Similarly, inhibition of NFκ B signaling by DMF, PMX464 or NBDII resulted in necroptotic cell death in CEM cells ( Supplementary Fig. S6C,D) . Thus, inhibitors of NFκ B signaling can mediate necroptosis via the ripoptosome. LCL161 35 , which induces necroptosis in a variety of cell lines when treated together with zVad, was included as control ( Supplementary Fig. S6C) .
Consistent with the notion that malignant T-cells can die in an apoptotic or necroptotic manner, a similar mode of PCD was observed in stimulated T-cells ( Supplementary Fig. S6E,F) . PCD in response to DMF-dependent NFκ B inhibition was elevated in stimulated T-cells (Supplementary Fig. S6E ). In contrast to unstimulated T-cells, which exclusively die by apoptosis, PCD in stimulated T-cells was characterized by apoptosis and/or necroptosis upon caspase inhibition ( Supplementary Fig. S6F ), suggesting that stimulated as well as malignant T-cells share a similar phenotype revealing NFκ B dependency. Furthermore, PCD was induced by ripoptosome formation because caspase-8 was complexed with RIPK1 upon DMF application in Sézary cells (Fig. 6D,E) . Importantly, Sézary patients orally treated with DMF revealed substantial ripoptosome formation compared to untreated healthy donors (Fig. 6F) . Moreover, caspase-3 cleavage was augmented in a majority of isolated CD4+ cells from patient II indicating that DMF induces PCD in Sézary patients via the ripoptosome (Fig. 6G) . Thus, application of DMF in Sézary patients may represent a promising approach for treatment of CTCL and other NFκ B-dependent tumors.
Discussion
NFκ B is a promising target for treatment of lymphoproliferative diseases e.g. CTCL. So far a variety of NFκ B Inhibitors have been tested such as Velcade ® , curcumin and nonsteroidal anti-inflammatory therapeutics [36] [37] [38] . However, these drugs reveal limited therapeutic responses or are too toxic for clinical application. In contrast, DMF is a FDA approved drug used for treatment of psoriasis and multiple sclerosis displaying minor side effects. Previously, it has been shown that DMF application suppresses tumor growth and metastasis in a mouse CTCL xenograft model 20 . Therefore, it is of particular interest to investigate the inhibitory activity of DMF for the development of a novel class of improved NFκ B inhibitors.
Here we show that therapeutic intervention targeting the NFκ B signaling pathway in malignant T-cells results in cell death that is mediated by the ripoptosome. DMF has been reported to inhibit NFκ B nuclear translocation, which leads to diminished production of pro-inflammatory cytokines and adhesion molecules 39, 40 . Mechanistically, it was shown that DMF interferes with intracellular thiols 40 . Trx1 is a cellular redox scavenger, which is active when its reactive cysteine residues (C32, C35) are reduced 41 . Thioredoxin reductase 1 (TrxR1) can reduce oxidized C32 and C35 and, therefore, controls the activity of Trx1. The interaction of Trx1 and thioredoxin reductase is regulated by C73 another cysteine in vicinity to the postulated interaction side of both proteins 24, 26 . Cancer cells often reveal elevated expression of active Trx1 and TrxR1, which maintains a reduced nuclear redox state providing an excellent environment for transcriptional activity 42 . We show that DMF modifies Trx1 at C73 leading to an inhibition of Trx1. NFκ B is a redox-regulated transcription factor. Trx1 reduces NFκ B in the nucleus and, thereby, enhances DNA-binding activity. Although it is possible that DMF influences other proteins apart from NFκ B, depletion of IAPs coincided with the gene-induction profile upon NFκ B inhibition. Loss of IAPs is associated with PCD triggered by DMF. Our experiments revealed that DMF-dependent induction of PCD was independent of death receptor engagement. Further, NFκ B inhibition did not result in altered expression of death ligands such as TNF, CD95L and TRAIL in lymphoma cells. This indicates that the complex consisting of caspase-8, RIPK1 and FADD formed in response to NFκ B inhibition is the intrinsic cell death platform called ripoptosome. In addition, our data indicate that a mitochondrial amplification loop improves ripoptosome formation in the T-ALL cell line CEM. This amplification loop is characterized by ripoptosome-dependent caspase-8 activity responsible for Smac-dependent degradation of IAPs and, thus, increased ripoptosome assembly ( Supplementary Fig. S7 ). Therefore, it is likely that the extent of ripoptosome formation depends on induction of the mitochondrial amplification loop. In turn the amount of ripoptosome formation determines the extent of apoptotic and necroptotic cell death: Treatment with LCL161 (less dependent on the mitochondrial amplification loop) results in strong necroptotic cell death when caspase-8 is inhibited. In contrast, DMF or etoposide induce a weak ripoptosome initially. Caspase-8 activity is required to enhance assembly of the ripoptosome via mitochondria. Accordingly, once caspase-8 activity is blocked by zVad, the mitochondrial amplification loop is lacking and ripoptosome formation is not augmented. Thus, induction of necroptosis upon zVad administration is less profound compared to LCL161 treated cells (Supplementary Fig. S8 ).
In summary, our observations show that inhibition of Trx1 results in diminished NFκ B transcriptional engagement. DMF-dependent suppression of NFκ B leads to downregulation of cIAP2 and cFLIP, which negatively regulate ripoptosome formation. Ripoptosome assembly is associated with caspase-8 activity, which promotes the mitochondrial amplification loop. This molecular mechanism provides important new information for prospective therapeutic interventions in cancer. Depending on the cellular context, elevated expression of anti-apoptotic Bcl-2 family members protecting mitochondria might dampen the ripoptosome-dependent response upon DMF administration. Thus, a combination of ripoptosome-inducing agents, such as Trx1 antagonists and inhibitors of Bcl-2 family members, might improve the anti-tumor responses.
Of note, non-stimulated T-cells exclusively die by apoptosis. In contrast, pre-activated as well as malignant CD4 + T-cells, which share a similar phenotype, can die by necroptosis once caspase-8 activity is inhibited. This is in agreement with a report that necroptosis occurs as a result of antigen receptor-mediated activation in caspase-8 deficient T-cells 13 . The additional cell death pathway in form of necroptosis in pre-activated or malignant T-cells could point to an important checkpoint for T-cell homeostasis. Moreover, necroptosis has been implied to release massive amounts of damage-associated molecular patterns (DAMPs) 43 . Hence, necroptotic cell death of CTCL might trigger a strong inflammatory anti-tumor response.
Finally, our results demonstrate that inhibition of NFκ B via Trx1 leads to ripoptosome formation and subsequent cell death in malignant T-cells. DMF exhibits only minor side effects compared to other anti-cancer drugs including Smac mimetics and therapeutic agents directly inhibiting NFκ B. Therefore, targeting the Trx1 system including Trx1 and TrxR1 is a promising therapeutic approach. Accordingly, DMF represents a novel substance class of small-molecule inhibitors to treat lymphoproliferative diseases and other tumors with constitutive NFκ B activation.
Materials and Methods
Chemicals. Chemicals Antibodies. Anti-caspase-8 monoclonal antibody C15 recognizes the p18 subunit of caspase-8. Anti-FLIP monoclonal antibody NF6 recognizes the N-terminal part of c-FLIP. Anti-FADD monoclonal antibody 1C4 recognizes the C-terminal part of FADD 46 . Antibodies against Caspase-3, caspase-9, p65, Phospho-NFκ B p65 (Ser536), cIAP1, cIAP2, XIAP, Bcl XL , and Smac were obtained from Cell Signaling. Antibodies specific for Bcl-2 were purchased from Santa Cruz Biotechnology, RIPK1 from BD Bioscience, Trx and Tom20 from Abcam, β -Actin from Genetech and Tubulin from Sigma.
Cell death assays and Luciferase activity assays. Cell death was analyzed by FSC/SSC or Annexin V-FiTC/7-Aminoactinomycin D (7AAD) staining using flow cytometry as described previously 47 . Specific cell death was calculated 29 . To determine mitochondrial membrane potential (∆ Ψ m ), cells were incubated with 50 μ M Tetramethylrhodamine ethyl ester (TMRE, Life Technologies) for 30 min. Caspase activity was measured using Caspase-Glo assay system (Promega) according to manufacturer's recommendations.
Thioredoxin activity assay. The Thioredoxin Activity Fluorescent Assay Kit (Cayman) uses fluorescence to measure active Trx in microtiter plates and was performed according to manufacturer's recommendations. The method is based on the reduction of insulin by reduced Trx.
Immunoprecipitation and pull-down assays. For co-immunoprecipitation of caspase-8 bound proteins, 1-2 × 10 7 cells were pre-stimulated with zVad (25 μ M) 30 min prior to treatment with indicated substances. Caspase-8 was precipitated according to manufacturer's instructions (Promega). Equal amounts of eluates were analyzed by Western blot.
Two complementary biotinylated oligonucleotides containing NFκ B binding sites were annealed and 1 μ g of double stranded oligonucleotides was incubated with 400 μ g of nuclear extracts in 500 μ l binding buffer (12% glycerol, 12 mM HEPES, pH 7.9, 4 mM Tris, pH 7.9, 150 mM KCl, 1 mM EDTA, 1 mM DTT, 0.1 μ g/μ l poly (dI-dC) and 0.5 μ g/μ l BSA). Protein complexes bound to each oligonucleotide were precipitated with preblocked streptavidin beads (Life Technologies), and analyzed by Western blot. For oligonucleotide sequences see Supplementary Information.
For pull-down of free thiols, cells were lysed with low pH buffer (50 mM 2-(N-morpholino) ethanesulfonic acid, pH 6.5), containing 1% Triton X-100 (v/v),100 mM NaCl, and Complete-Mini protease inhibitor cocktail (Roche). Proteins containing free thiols incubated with biotinylated iodoacetamide (100 μ M, BIAM, Life technologies) were precipitated with 50 μ l Streptavidin beads pre-adsorbed with 1 mg/ml BSA. Proteins with accessible thiol groups were analyzed by Western blot.
Immunofluorescence. Immunofluorescent stainings and acquisition of mean fluorescence intensities (MFIs) were performed as described 48 . Primary antibodies (Smac, FADD (Abcam), caspase-8 (Santa Cruz), RIPK1 (BD Bioscience)), fluorophore-conjugated secondary antibodies and Hoechst33342 (Life Technologies) were diluted 1:50-1:100. For staining of mitochondria MitoTracker Deep Red (Life technologies) was added to secondary antibodies.
To visualize protein interactions a Proximity Ligation Assay (PLA) was performed according to manufacturer's recommendations (Sigma). Immunofluorescent stainings were analyzed by confocal microscopy (LSM710, Zeiss).
Lymphocyte separation. Human peripheral blood leukocytes were purified as described 29 . Then, T-cells were sorted with the CD4 + T-Cell Isolation Kit II according to manufacturer's instruction (Miltenyi Biotec). The study was conducted according to ethical guidelines of the DKFZ and the Helsinki Declaration, and was approved by the ethics committee II of the Ruprecht-Karls-University of Heidelberg.
